印刷

診療科・部門紹介
診療科・部門紹介

放射線治療部

放射線治療部

最終更新日 : 2021年4月2日

放射線治療部とは診療科の特徴|診療・研究実績|スタッフ紹介放射線治療装置

診療実績

原発巣別新規患者数 (新患実人数)

 原発巣別 2015年 2016年 2017年 2018年 2019年 2020年
1.脳・脊髄 3 1 0 1 1 0
2.頭頸部 213 251 213 202 231 174
3.食道 103 84 84 107 95 92
4.肺・気管・縦隔 145 165 141 166 150 130
4-a.うち肺 139 157 134 164 144 124
5.乳腺 361 419 450 381 427 422
6.肝・胆・膵 21 19 23 25 33 23
7.胃・小腸・結腸・直腸 186 173 168 183 162 171
8.婦人科 121 83 88 96 110 103
9.泌尿器系 165 147 139 159 138 161
9-a.うち前立腺 128 116 106 123 110 125
10.造血器リンパ系 81 98 70 77 57 62
11.皮膚・骨・軟部 62 60 51 49 44 57
12.その他 (悪性) 22 11 12 11 16 15

 

脳および骨転移治療患者実人数 (新患+再患)

 転移部位 2015年 2016年 2017年 2018年 2019年 2020年
1.脳転移 87 98 91 97 98 73
2.骨転移 332 304 331 301 271 250

特殊な放射線治療患者実人数(新患+再患)

 特殊な放射線治療 2015年 2016年 2017年 2018年 2019年 2020年
1.脳定位放射線治療 0 0 3 21 17 16
2.体幹部定位放射線治療 34 40 25 35 35 63
3.強度変調放射線治療(IMRT) 298 320 319 436 598 691
4.小線源治療 81 60 64 68 76 65

放射線治療部 研究業績

医師

学会発表

2018年

  1. Yoshioka Y. (Symposium, invited) Long-term results of HDR monotherapy in the treatment of prostate cancer. ESTRO 37 (European Society for Radiotherapy and Oncology, 37th annual meeting), Barcelona, Spain, April 22, 2018
  2. 吉岡靖生: シンポジウム:高線量率組織内照射(HDR)単独療法(シンポジウム:我が国にける高リスク・超高リスク前立腺がんの治療成績−局所治療が原病死リスク低減にどこまで貢献可能か?−). 第106回日本泌尿器科学会総会. 2018. 京都.
  3. 吉岡靖生: 前立腺癌の放射線治療(外部照射・小線源). 第20回放射線腫瘍学夏季セミナー. 2018. 埼玉.
  4. Taguchi S, Oguchi M, Yamaguchi M, Suzuki R, Ejima Y, Hasegawa M, Ishibashi N, Isobe K, Kasuya T, Sasai K, Shimoda E, Soejima T, Imai M. The Primary Tumor Invasion and Soluble Interleukin-2 Receptor as Prognostic Factors for Localized Nasal NK/T-cell Lymphoma: the Multi-institutional Retrospective Study u(NKEA project) in Japan. The 2018 Annual Meeting of the American Society for Radiation Oncology; Oct 2018. Texas, USA.
  5. 田口千藏, 小口正彦, 山口素子, 鈴木律朗, 江島泰生, 長谷川正俊, 石橋直也, 磯部公一, 糟谷健夫, 笹井啓資, 下田絵美子, 副島俊典, 今井美智子. 限局期鼻腔NK/T細胞リンパ腫のPTIおよびsIL-2Rの予後予測に関する検討. 日本放射線腫瘍学会第31回学術大会. 2018. 京都.
  6. 鈴木涼子ほか. Twice-daily TRT for small cell lung cancer dose not increase the risk of acute severe esophagitis. 日本放射線腫瘍学会第31回学術大会. 2018. 京都.
  7. 鈴木涼子ほか. Re-irradiation of brain recurrence after whole brain irradiation for small cell lung cancer. 日本放射線腫瘍学会第31回学術大会. 2018. 京都.
  8. 鈴木涼子ほか. Hematologic prognostic factors of brain failure in patients with small cell lung cancer. 日本放射線腫瘍学会第31回学術大会. 2018. 京都.
  9. 佐々木理栄, 田口千藏, 桑原宏文, 吉岡靖生, 篠崎英司, 長嵜寿矢, 秋吉高志, 小西 毅, 福長洋介, 上野雅資, 小口正彦. 肛門管浸潤を有する下部進行直腸癌に対する術前化学放射線療法の予防領域に関する検討. 日本放射線腫瘍学会第31回学術大会. 2018. 京都.

2019年

  1. Yoshioka Y. (Invited speaker) Current status and perspectives of high-dose-rate brachytherapy for prostate cancer. 16th National Meeting of Chinese Society of Therapeutic Radiation Oncology (CSTRO). Oct 2019. Shenzhen, China.
  2. 吉岡靖生: ランチョンセミナー: 前立腺癌のホルモン療法 〜放射線科医の観点から〜. ガイドラインから見た放射線療法とホルモン療法の考え方. 第107回日本泌尿器科学会総会. 2019. 名古屋.
  3. 吉岡靖生: イブニングセミナー: VISICOIL最前線2019: VISICOILとSpaceOARを用いた前立腺IGRT (TrueBeam). 日本放射線腫瘍学会第32回学術大会. 2019. 名古屋.
  4. 吉岡靖生: シンポジウム: 前立腺癌各種治療法の特徴: 高線量率組織内照射. 日本放射線腫瘍学会第32回学術大会. 2019. 名古屋.
  5. 吉岡靖生: ランチョンセミナー: よりよい前立腺がん治療を目指して 泌尿器科、放射線科の立場から 〜ハイドロゲルスペーサを用いた治療経験〜. 日本放射線腫瘍学会第32回学術大会. 2019. 名古屋.
  6. Taguchi S, Yoshioka Y, Mishima Y, Nishimura N, Yokoyama M, Takeuchi K, Terui Y, Oguchi M. Assessment of Late Toxicities of Liver and Kidney after Definitive Radiotherapy for Gastric MALT Lymphoma. The 2019 Annual Meeting of the American Society for Radiation Oncology; Sep. 2019. Chicago, USA.
  7. 田口千藏, 吉岡靖生, 三嶋裕子, 西村倫子, 横山雅大, 竹内賢吾, 照井康仁, 小口正彦. 胃MALTリンパ腫放射線治療後の肝臓および腎臓の晩期毒性に関する検討. 日本放射線腫瘍学会第32回学術大会. 2019. 名古屋.
  8. 鈴木涼子、吉田匡宏、小口正彦、吉岡靖生、徳増 健二、大迫智、大野真司、上野貴之、宮城由美 Efficacy of radiation for focally tumor-exposed margin after breast conserving surgery: an update. 日本放射線腫瘍学会第32回学術大会. 2019. 名古屋.
  9. 篠村一磨、鈴木涼子、小塚拓洋、吉岡靖生、小口正彦 椎体の転移性骨腫瘍に対するIMRTによる再照射の有用性の検討 日本放射線腫瘍学会第32回学術大会. 2019. 名古屋.
  10. 佐々木理栄, 田口千藏, 桑原宏文, 吉岡靖生, 篠崎英司, 長嵜寿矢, 秋吉高志, 小西 毅, 福長洋介, 上野雅資, 小口正彦. 肛門管浸潤を有する下部進行直腸癌に対する術前化学放射線療法の予防領域に関する検討. 第57回日本癌治療学会学術集会. 2019. 福岡.

2020年

  1. 吉岡靖生, 伊藤誠,高瀬裕樹, 鈴木淳司, 奥田隆仁, 小口正彦. シンポジウム:体幹部定位放射線治療のトピックス:前立腺癌に対する体幹部定位放射線治療. 第29回日本定位放射線治療学会. 2020. 東京→WEB開催.
  2. Taguchi S, Sasaki R, Yoshioka Y, Mishima Y, Nishimura N, Yokoyama M, Terui Y, Takeuchi K, Tsuji H, Oguchi M. Prognosis and Patterns of Relapse after Radiotherapy for Localized Ocular Adnexal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue (MALT Lymphoma). The 2020 Annual Meeting of the American Society for Radiation Oncology; Oct. 2020. Virtual Meeting.
  3. 佐々木理栄, 田口千藏, 吉岡靖生, 中島大, 伊藤裕志, 三嶋裕子, 西村倫子, 横山雅大, 照井康仁, 竹内賢吾, 辻 英貴, 小口正彦. 限局期眼付属器MALTリンパ腫に対する根治的放射線治療後の白内障に関する検討. 日本放射線腫瘍学会第33回学術大会. 2020.10. WEB開催.

著書・論文

2018年

  1. Nakajima N, Oguchi M, Kumai Y, Yoshida M, Inoda H, Yoshioka Y, Iwase T, Ito Y, Akiyama F, Ohno S. Clinical outcomes and prognostic factors in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy followed by surgery and postmastectomy radiation therapy in the modern treatment era. Adv Radiat Oncol 2018;3:271–279
  2. Suzuki R, Wei X, Allen PK, Welsh JW, Cox JD, Komaki R, Lin SH. Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis. Radiat Oncol. 2018;13:258.
  3. Suzuki R, Wei X, Allen PK, Welsh JW, Cox JD, Komaki R, Lin SH. Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis. Clin Lung Cancer. 2018;19:e885-e891.
  4. Suzuki R, Lin SH, Wei X, Allen PK, Welsh JW, Byers LA, Komaki R. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol. 2018;126:499-505.
  5. Suzuki R, Wei X, Allen PK, Welsh JW, Cox JD, Komaki R, Lin SH. Hematologic variables associated with brain failure in patients with small-cell lung cancer. Radiother Oncol. 2018;128:505-512.
  6. Suzuki R, Komaki R. Is prophylactic cranial irradiation indicated for patients with extensive-stage small cell lung cancer with a complete response to first-line treatment? Radiother Oncol. Radiother Oncol. 2018;127:339-343.
  7. Koike Y, Sumida I, Mizuno H, Shiomi H, Kurosu K, Ota S, Yoshioka Y, Suzuki O, Tamari K, Ogawa K. Dosimetric impact of intra-fraction prostate motion under a tumour-tracking system in hypofractionated robotic radiosurgery. PLoS One 2018;13: e0195296
  8. Yamazaki H, Masui K, Suzuki G, Nakamura S, Shimizu D, Nishikawa T, Okabe H, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K. High-dose-rate brachytherapy monotherapy versus image-guided intensity-modulated radiotherapy with helical tomotherapy for patients with localized prostate cancer. Cancers (Basel) 2018;10:322
  9. Murofushi KN, Kitamura N, Yoshioka Y, Sumi M, Ishikawa H, Oguchi M, Sakurai H. A clinical evaluation of American Brachytherapy Society consensus guideline for bulky vaginal mass in gynecological cancer. Int J Gynecol Cancer 2018;28:1438–1445
  10. Yamazaki H, Masui K, Suzuki G, Nakamura S, Aibe N, Shimizu D, Nishikawa T, Okabe H, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K. Radiothrerapy for elderly patients aged ≥75 years with clinically localized prostate cancer-Is there a role of brachytherapy? J Clin Med 2018;7:424
  11. Yamazaki H, Masui K, Suzuki G, Nakamura S, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K. Comparison of three moderate fractionated schedules employed in high-dose-rate brachytherapy monotherapy for clinically localized prostate cancer. Radiother Oncol 2018;129:370–376
  12. Kanayama N, Kierkels RGJ, Schaaf A, Steenbakkers RJHM, Yoshioka Y, Nishiyama K, Fujii T, Ogawa K, Langendijk JA, Teshima T. External validation of a multifactorial normal tissue complication probability model for tube feeding dependence at 6smonths after definitive radiotherapy for head and neck cancer. Radiother Oncol 2018;129:403–408
  13. Murofushi KN, Nakajima M, Tomita T, Sumi M, Yoshioka Y, Oguchi M, Sakurai H. Impact of visual feedback on dose-volume histograms for organs at risk in postoperative radiotherapy with deep inspiration breath-holding for patients treated with breast-conserving therapy: a planning study. Breast Cancer 2018;25:656–662
  14. Varnava M, Sumida I, Mizuno H, Shiomi H, Suzuki O, Yoshioka Y, Ogawa K. A new plan quality objective function for determining optimal collimator combinations in prostate cancer treatment with stereotactic body radiation therapy using CyberKnife. PLoS One 2018;13:e0208086.
  15. Yamaguchi M, Oguchi M, Suzuki R. Extranodal NK/T-cell lymphoma: Updates in biology and management strategies. Best Pract Res Clin Haematol. 2018;31(3):315-321.
  16. Yoshida K, Otani Y, Nose T, Yoden E, Asahi S, Tsukiyama I, Dokiya T, Saeki T, Fukuda I, Sekine H, Kumazaki Y, Takahashi T, Kotsuma T, Masuda N, Nakashima K, Matsumura T, Nakagawa S, Tachiiri S, Moriguchi Y, Itami J, Oguchi M. Case report of a dose-volume histogram analysis of rib fracture after accelerated partial breast irradiation: interim analysis of a Japanese prospective multi-institutional feasibility study. J Contemp Brachytherapy. 2018;10(3):274-278.
  17. Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood. 2018;131(23):2528-2540.
  18. Yamaguchi M, Suzuki R, Kim SJ, Ko YH, Oguchi M, Asano N, Miyazaki K, Terui Y, Kubota N, Maeda T, Kobayashi Y, Amaki J, Soejima T, Saito B, Shimoda E, Fukuhara N, Tsukamoto N, Shimada K, Choi I, Utsumi T, Ejima Y, Kim WS, Katayama N. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy. Cancer Sci. 2018;109(6):2056-2062.
  19. Ishibashi N, Soejima T, Kawaguchi H, Akiba T, Hasegawa M, Isobe K, Ito H, Imai M, Ejima Y, Hata M, Sasai K, Shimoda E, Maebayashi T, Oguchi M, Akimoto T; Japanese Radiation Oncology Study Group. National survey of myeloablative total body irradiation prior to hematopoietic stem cell transplantation in Japan: survey of the Japanese Radiation Oncology Study Group (JROSG). J Radiat Res. 2018;59(4):477-483.
  20. Ng AK, Yahalom J, Goda JS, Constine LS, Pinnix CC, Kelsey CR, Hoppe B, Oguchi M, Suh CO, Wirth A, Qi S, Davies A, Moskowitz CH, Laskar S, Li Y, Mauch PM, Specht L, Illidge T. Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;100(3):652-669.
  21. Tsuyama N, Asaka R, Dobashi A, Baba S, Mishima Y, Ueda K, Oguchi M, Tsuji H, Hatake K, Takeuchi K. Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation. Hematol Oncol. 2018;36(1):328-335.

2019年

  1. Yoshioka Y, Itami J, Oguchi M, Nakano T. Preface. In: Yoshioka Y, Itami J, Oguchi M, Nakano T (eds.). Brachytherapy: Techniques and Evidences. Springer Nature Singapore 2019, vii
  2. Yoshioka Y, Sumi M, Oguchi M. High-dose-rate brachytherapy as monotherapy for prostate cancer. In: Yoshioka Y, Itami J, Oguchi M, Nakano T (eds.). Brachytherapy: Techniques and Evidences. Springer Nature Singapore 2019, pp181–197
  3. Suzuki R, Wei X, Allen PK, Cox JD, Komaki R, Lin SH. Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer. Clin Lung Cancer. 2019;20:117-123.
  4. Yamazaki H, Masui K, Suzuki G, Nakamura S, Yamada K, Okihara K, Shiraishi T, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer. Radiother Oncol 2019;132:162–170
  5. Yamazaki H, Masui K, Suzuki G, Nakamura S, Aibe N, Shimizu D, Yamada K, Okihara K, Shiraishi T, Kotsuma T, Yoshida K, Tanaka E, Otani K, Yoshioka Y, Ogawa K, Nishikawa T, Okabe H. Effect of androgen deprivation therapy on other-cause of mortality in elderly patients with clinically localized prostate cancer treated with modern radiotherapy: Is there a negative impact? J Clin Med 2019;8:338
  6. Yamazaki H, Masui K, Suzuki G, Nakamura S, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K. Influence of transitioning of planning techniques in high-dose-rate brachytherapy monotherapy for clinically localized prostate cancer from two- to three-dimensional planning. Brachytherapy 2019;18:589–597
  7. Morimoto M, Bijl HP, Schaaf AVD, Xu CJ, Steenbakkers RJHM, Chouvalova O, Yoshioka Y, Teshima T, Langendijk JA. Development of normal tissue complication probability model for trismus in head and neck cancer patients treated with radiotherapy: The role of dosimetric and clinical factors. Anticancer Res 2019;39:6787–6798
  8. Tominaga T, Akiyoshi T, Yamamoto N, Taguchi S, Mori S, Nagasaki T, Fukunaga Y, Ueno M. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. PLoS One. 2019;14(2):e0212978.
  9. Konishi T, Shinozaki E, Murofushi K, Taguchi S, Fukunaga Y, Nagayama S, Fujimoto Y, Akiyoshi T, Nagasaki T, Suenaga M, Chino A, Kawachi H, Yamamoto N, Ishikawa Y, Oguchi M, Ishizuka N, Ueno M, Yamaguchi K. Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer. Ann Surg Oncol. 2019;26(8):2507-2513.
  10. Sapienza LG, Ning MS, Taguchi S, Calsavara VF, Pellizzon ACA, Gomes MJL, Kowalski LP, Baiocchi G. Altered-fractionation radiotherapy improves local control in early-stage glottic carcinoma: A systematic review and meta-analysis of 1762 patients. Oral Oncol. 2019;93:8-14.
  11. Takano S, Omura M, Suzuki R, Tayama Y, Matsui K, Hashimoto H, Hongo H, Nagata H, Tanaka K, Hata M, Inoue T. Intensity-modulated radiation therapy using TomoDirect for postoperative radiation of left-sided breast cancer including lymph node area: comparison with TomoHelical and three-dimensional conformal radiation therapy. J Radiat Res. 2019;60:694-704.
  12. Yamauchi C, Yoshimura M, Sekiguchi K, Hamamoto Y, Nakajima N, Sanuki N, Ogo E, Oguchi M, Saji S, Iwata H. The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition. Breast Cancer. 2020;27(1):9-16.
  13. Kawaguchi H, Soejima T, Ishibashi N, Akiba T, Hasegawa M, Isobe K, Ito H, Imai M, Ejima Y, Hata M, Sasai K, Shimoda E, Oguchi M, Akimoto T. National survey on total-body irradiation prior to reduced-intensity stem cell transplantation in Japan: The Japanese Radiation Oncology Study Group. J Radiat Res. 2019;60(5):579-585.
  14. Kondo K, Matsusaka S, Ishihara S, Horie H, Uehara K, Oguchi M, Murafushi K, Ueno M, Mizunuma N, Shimbo T, Kato D, Okuda J, Hashiguchi Y, Nakazawa M, Sunami E, Kawai K, Yamashita H, Okada T, Ishikawa Y, Fujii M, Nakajima T. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial). Radiother Oncol. 2019;134:199-203.
  15. Yamaguchi M, Suzuki R, Miyazaki K, Amaki J, Takizawa J, Sekiguchi N, Kinoshita S, Tomita N, Wada H, Kobayashi Y, Niitsu N, Ando T, Maeda T, Saito B, Matsuoka H, Sakai R, Kubota N, Masaki Y, Kameoka Y, Asano N, Oguchi M, Katayama N. Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin. Ann Hematol. 2019;98(7):1647-1655.
  16. Binkley MS, Brady JL, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Ahmed S, MacManus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova YM, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Mikhaeel NG, Hoppe RT. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. Int J Radiat Oncol Biol Phys. 2019;104(3):522-529.
  17. Tsuyama N, Yokoyama M, Fujisaki J, Oguchi M, Terui Y, Takeuchi K. Villous colonization (glove balloon sign): A histopathological diagnostic marker for follicular lymphomas with duodenal involvement including duodenal-type follicular lymphoma. Pathol Int. 2019;69(1):48-50.
  18. Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Mac Manus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova Y, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Hoppe RT, Mikhaeel NG. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood. 2019;133(3):237-245.

2020年

  1. Suzuki R, Yoshida M, Oguchi M, Yoshioka Y, Tokumasu K, Osako T, Ono S, Ueno T, Miyagi Y. Efficacy of radiation boost after breast-conserving surgery for breast cancer with focally positive, tumor-exposed margins. J Radiat Res. 2020 May 22;61(3):440-446. doi: 10.1093/jrr/rraa005.
  2. Suzuki R, Yoshida M, Oguchi M, Yoshioka Y, Tokumasu K, Osako T, Ono S, Ueno T, Miyagi Y. Efficacy of radiation boost after breast-conserving surgery for breast cancer with focally positive, tumor-exposed margins. J Radiat Res. 2020; 61(3): 440–446.
  3. Sasamura K, Suzuki R, Kozuka T, Yoshimura R, Yoshioka Y, Oguchi M. Outcomes after reirradiation of spinal metastasis with stereotactic body radiation therapy (SBRT): a retrospective single institutional study. J Radiat Res. 2020;61(6):929-934.
  4. 篠村一磨、吉岡靖生、小口正彦 【画像診断医にも知ってほしい放射線治療:画像が担う役割】画像情報の利用 治療計画立案からフォローアップまで 前立腺癌 臨床画像36巻2号166-174.2020
  5. Murofushi KN, Yoshioka Y, Ishikawa H, Sumi M, Okumura T, Oguchi M, Sakurai H. Selection criteria and clinical outcomes of patients with asymmetrical cervical cancer treated with various high-dose-rate brachytherapy techniques. Anticancer Res 2020;40:999–1006
  6. Uchida H, Hirata T, Otani K, Suzuki O, Oda M, Akino Y, Sumida I, Hatano K, Fujita K, Uemura M, Imamura R, Eino D, Yoshioka Y, Nonomura N, Ogawa K. Assessment of daily replanning and geometrical variation of high-dose-rate brachytherapy for the prostate. Anticancer Res 2020;40:1677–1682
  7. Murofushi K, Yoshioka Y, Sumi M, Ishikawa H, Oguchi M, Sakurai H. Outcomes analysis of pre-brachytherapy MRI in patients with locally advanced cervical cancer. Int J Gynecol Cancer 2020;30:473–479
  8. Nakamura R, Hirata T, Suzuki O, Otani K, Kai N, Hatano K, Fujita K, Uemura M, Imamura R, Tanaka K, Yoshioka Y, Nonomura N, Ogawa K. Stereotactic body radiotherapy using CyberKnife® for localized low- and intermediate-risk prostate cancer: Initial report on a phase I/II trial. Anticancer Res 2020;40:2053–2057
  9. Kim H, Jeong H, Yamaguchi M, Sohn I, Yoon SE, Byeon S, Hur JY, Koh Y, Yoon SS, Kim EJ, Oguchi M, Miyazaki K, Taguchi S, Yoon DH, Cho J, Ko YH, Kim SJ, Suzuki R, Kim WS. Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood. 2020;136(22):2548-2556.
  10. Nakanishi R, Akiyoshi T, Toda S, Murakami Y, Taguchi S, Oba K, Hanaoka Y, Nagasaki T, Yamaguchi T, Konishi T, Matoba S, Ueno M, Fukunaga Y, Kuroyanagi H. Radiomics Approach Outperforms Diameter Criteria for Predicting Pathological Lateral Lymph Node Metastasis After Neoadjuvant (Chemo)Radiotherapy in Advanced Low Rectal Cancer. Ann Surg Oncol. 2020;27(11):4273-4283.
  11. Kim H, Jeong H, Yamaguchi M, Sohn I, Yoon SE, Byeon S, Hur JY, Koh Y, Yoon SS, Kim EJ, Oguchi M, Miyazaki K, Taguchi S, Yoon DH, Cho J, Ko YH, Kim SJ, Suzuki R, Kim WS. Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood. 2020;136(22):2548-2556.
  12. Yamano T, Tomita N, Sato T, Hayakawa K, Kamikonya N, Matoba S, Uki A, Baba H, Oya N, Hasegawa H, Shigematsu N, Hiraoka M, Shimada M, Noda M, Sakai Y, Sato H, Saegusa M, Takeuchi M, Oguchi M, Oya M, Watanabe M. Influence of chemoradiotherapy on nutritional status in locally advanced rectal cancer: Prospective multicenter study. Nutrition. 2020;77:110807.

放射線技師・医学物理士

学会発表

2018年

  1. Murakami Y, Matsubayashi F, Magome T, Takahashi R, Arima M, Kamima T, Nakano M, Sato T, Yoshioka Y, Oguchi M. Potential of jaw tracking technique in flattening filter-free beam for lung stereotactic body radiation therapy. American Association of Physicists in Medicine. Aug. 2018. Nashville, USA.

2019年

  1. Murakami Y, Magome T, Nakano M, Sato T, Yoshioka Y, Oguchi M. Effect of prostatic calcification on radiomic features extracted from computed tomography (CT). The Taiwan Society of Radiological Technologists (TWSRT) and the International Conference of Medical Imaging. Mar. 2019. Taichung, Taiwan.
  2. Murakami Y, Magome T, Mizutani T, Sato T, Yoshioka Y, Oguchi M. Potential of radiomic feature related to prostatic calcifications for the machine learning based prediction of biochemical recurrence in prostate cancer patient. American Society for Radiation Oncology. Nov. 2019. Chicago, USA.
  3. Nakano M, Imae T, Nakamoto T, Haga A, Nawa K, Nomura Y, Chhatkuli R, Demachi K, Takahashi W, Yamamoto K, Nakagawa K, Hashimoto M, Yoshioka Y, Oguchi M. Pseudo-CBCT image prediction of head and neck cancer patient using principal component vector fields of early treatment fractions. American Association of Physicists in Medicine. July 2019. San Antonio, USA.
  4. Nakano M, Imae T, Nakamoto T, Haga A, Nawa K, Takahashi W, Nakagawa K, Hashimoto M, Yoshioka Y, Oguchi M. Pseudo-CBCT image prediction of head and neck cancer patient using principal component vector fields of early treatment fractions. 第117回日本医学物理学会学術大会. 2019. 横浜.
  5. 上間達也, 村上悠, 有馬誠人, 佐藤洋輔, 吉岡稔, 佐藤智春. 強度変調回転照射の治療計画における開口形状コントローラーに関する基礎的検討. 日本放射線技術学会第47回秋季学術大会. 2019. 大阪.
  6. Miyauchi H, Takahashi H, Hasegawa T, Hashimoto M. Image processing method using super-resolution technique for exposure dose reduction. 第118回日本医学物理学会学術大会. 2019. 福井.
  7. 村上 悠, 上間達也, 松林史泰, 浅利崇生, 鈴木涼子, 中野正寛, 吉岡靖生, 小口正彦. VMATを用いた肺定位放射線治療におけるITV内のCT値の割り当てがGTV線量に及ぼす影響. 第32回日本高精度外部照射研究会. 2019. 東京.
  8. 藤本大夢, 高津淳, 杉本聡, 笹井啓資. マーカー追跡ログを使用したInter-/Intra-Fractionによる患者呼吸波形の変化の解析. 第32回日本高精度外部照射研究会. 2019. 東京.
  9. 村上 悠, 馬込大貴, 水谷拓也, 佐藤智春, 吉岡靖生, 小口正彦. 前立腺癌患者におけるRadiomics特徴量を用いた生化学的再発予測モデルの構築. 日本放射線腫瘍学会第32回学術大会. 2019. 名古屋.
  10. 藤本大夢, 高津淳, 原直哉, 大島理規, 鹿間直人 笹井啓資. 肺がんSBRTにおけるVMAT/3D-CRTの呼吸波形変化に対するロバスト性評価. 日本放射線腫瘍学会第32回学術大会. 2019. 名古屋.
  11. 津野隼人,佐々木浩二,坂本昌隆. Evaluation of uncertainty during measuring entrance surface dose in image-guided radiation therapy. 第75回日本放射線技術学会総会学術大会. 2019. 横浜.
  12. Tsuno H, Sasaki K, Shimizu M, Takase N, Takahashi T, Saotome S, Miyauchi H, Sato T. Evaluation of uncertainty in electrometer calibration factor measurement using 192Ir source after electrometer separated calibration. 第118回日本医学物理学会学術大会. 2019. 福井.
  13. 津野隼人, 佐々木浩二, 清水森人, 高瀬信宏, 佐藤智春. 分離校正を受けた電位計を基準とした電位計相互校正による電位計校正定数の経年変化と不確かさの評価. 第47回日本放射線技術学会秋季学術大会. 2019. 大阪.
  14. Fujimoto D, Takatsu J, Hara N, Sugimoto S, Sasai K. Evaluation of the dosimetric robustness for 4DCT based internal margin against respiratory motion variations of lung cancer. 第117回日本医学物理学会学術大会. 2019. 横浜.

2020年

  1. 村上 悠, 馬込大貴, 水谷拓也, 佐藤智春, 吉岡靖生, 小口正彦. 前立腺癌患者における前立腺内の石灰化が生化学的再発予測モデルに与える影響. 第33回高精度放射線外部照射部会学術大会. 2020. 福岡.
  2. Murakami Y, Magome T, Matsumoto K, Sato T, Yoshioka Y, Oguchi M. Automated dose generation for intensity-modulated radiation therapy using generative adversarial networks in prostate cancer patient. 第119回日本医学物理学会学術大会. 2020. 横浜.
  3. Miyauchi H, Takahashi H, Hasegawa T, Hashimoto M. Building deep learning based new super-resolution system for exposure dose reduction. 第119回日本医学物理学会学術大会. 2020. 横浜.
  4. Miyauchi H, Tanaka Y, Takahashi K, Nakano M, Hasegawa T, Hashimoto M. Image processing system by super-resolution using deep learning to exposure dose reduction. 2020 Joint American Association of Physicists in Medicine (AAPM) | Canadian Organization of Medical Physicists (COMP). July 2020. Vancouver, Canada.

著書・論文

2018年

  1. Murakami Y, Nakano M, Yoshida M, Hirashima H, Nakamura F, Fukunaga J, Hirose T, Yoshioka Y, Oguchi M, Hirata H. Possibility of chest wall dose reduction using volumetric-modulated arc therapy (VMAT) in radiation-induced rib fracture cases: comparison with stereotactic body radiation therapy (SBRT). J Radiat Res. 2018;59(3):327−332.
  2. Kamima T, Baba H, Takahashi R, Yamashita M, Sugawara Y, Kawai D, Yamamoto T, Satou A, Tachibana H. Multi-institutional comparison of computer-based independent dose calculation for intensity modulated radiation therapy and volumetric modulated arc therapy. Phys Med. 2018;45:72-81.
  3. Takahashi R, Kamima T, Itano M, Yamazaki T, Ishibashi S, Higuchi Y, Shimizu H, Yamamoto T, Yamashita M, Baba H, Sugawara Y, Sato A, Nishiyama S, Kawai D, Miyaoka S, Tachibana H. A multi-institutional study of secondary check of treatment planning using Clarkson-based dose calculation for three-dimensional radiotherapy. Phys Med. 2018;49:19-27.
  4. Matsubayashi F, Takahashi R, Yoshioka M, Toshiyasu T, Sato T. Impact of respiratory motion on dose variation in radiation therapy for glottic cancer. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2018;74(11):1269-1274.
  5. Jinno S, Tachibana H, Moriya S, Mizuno N, Takahashi R, Kamima T, Ishibashi S, Sato M. A multi-institutional study of independent calculation verification in inhomogeneous media using a simple and effective method of heterogeneity correction integrated with the Clarkson method. J Radiat Res. 2018;59 (4): 490-500.
  6. Takei H, Isobe T, Kitamura N, Mori Y, Tomita T, Kobayashi D, Kamizawa S, Sato T, Sakurai H, Sakae T. General ion recombination effect in a liquid ionization chamber in high-dose-rate pulsed photon and electron beams. J Radiat Res. 2018;59(3):282-285.
  7. Ueda Y, Fukunaga JI, Kamima T, Adachi Y, Nakamatsu K, Monzen H. Evaluation of multiple institutions' models for knowledge-based planning of volumetric modulated arc therapy (VMAT) for prostate cancer. Radiat Oncol. 2018;13(1):46.
  8. Tachibana H, Uchida Y, Miyakawa R, Yamashita M, Sato A, Kito S, Maruyama D, Noda S, Kojima T, Fukuma H, Shirata R, Okamoto H, Nakamura M, Takada Y, Nagata H, Hayashi N, Takahashi R, Kawai D, Itano M. Multi-institutional comparison of secondary check of treatment planning using computer-based independent dose calculation for non-C-arm linear accelerators. Phys Med, 2018;56:58-65.

2019年

  1. Murakami Y, Matsubayashi F, Magome T, Takahashi R, Arima M, Kamima T, Nakano M, Sato T, Yoshioka Y, Oguchi M. Evaluation of organ-at-risk dose reduction with jaw tracking technique in flattening filter-free beams in lung stereotactic body radiation therapy. Phys Med. 2019;61:70−76.
  2. Kamima T, Ueda Y, Fukunaga J, Shimizu・Y, Tamura M, Ishikawa・ K, Monzen H. Multi-institutional evaluation of knowledge-based planning performance of volumetric modulated arc therapy (VMAT) for head and neck cancer. Phys Med. 2019;64:174-181.
  3. Kamima T, Yoshioka M, Takahashi R, Sato T. Impact of DVH Outliers Registered in Knowledge-based Planning on Volumetric Modulated Arc Therapy Treatment Planning for Prostate Cancer. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2019;75(2):151-159.
  4. Matsubayashi F, Takahashi R, Kamima T, Sato Y, Sato T. Influence of respiratory phase during image acquisition on prescribed dose in image guided radiation therapy using implant marker for prostate cancer. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2019;75(12):1394-1402.
  5. 伊藤康. 診療放射線技師から見た「平成の医療業界」. Rad Fan. 2019;17(6):64-66.
  6. 佐藤智春. 平成そして令和へ 診療放射線技師より. 臨床放射線. 2019;64(10):1291-1297.
  7. Yamashita M, Takahashi R, Kokubo M, Takayama K, Tanabe H, Sueoka M, Ishii M, Tachibana H. A feasibility study of independent verification of dose calculation for Vero4DRT using a Clarkson-based algorithm. Med Dosim. 2019;44(1):20-25.

2020年

  1. Murakami Y, Magome T, Matsumoto K, Sato T, Yoshioka Y, Oguchi M. Fully automated dose prediction using generative adversarial networks in prostate cancer patients. PLoS ONE. 2020;15(5): e0232697.
  2. Kamima T, Murakami Y, Arima M, Sato Y, Yoshioka M, Sato T. Impact of Aperture Shape Controller on Volumetric Modulated Arc Therapy Treatment Planning for Nasopharyngeal Cancer. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2020;76(4):356-365.
  3. Nakanishi R, Akiyoshi T, Toda S, Murakami Y, Taguchi S, Oba K, Nagasaki T, Matoba S, Ueno M, Fukunaga Y, Kuroyanagi H. Radiomics approach outperforms diameter criteria for predicting pathological lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in advanced low rectal cancer. Ann Surg Oncol. 2020;27:4273-4283.
  4. Tamura M, Monzen H, Matsumoto K, Kubo K, Ueda Y, Kamima T, Inada M, Doi H, Nakamatsu K, Nishimura Y. Influence of cleaned-up commercial knowledge-based treatment planning on volumetric-modulated arc therapy of prostate cancer. Journal of Medical Physics. 2020;45(2): 71-77.
  5. Monzen H, Tamura M, Ueda Y, Fukunaga J, Kamima T, Muraki Y, Kubo K, Nakamatsu K. Dosimetric evaluation with knowledge-based planning created at different periods in volumetric-modulated arc therapy for prostate cancer: a multi-institution study. Radiol Phys Technol. 2020;13(4):327-335.

特許・受賞歴等

  1. 村上 悠 “がん研究振興財団 看護師・薬剤師・技師等海外研修派遣員” 2018.
  2. 中野正寛 文部科学省科学研究費 研究活動スタート支援 
  3. 中野正寛 文部科学省科学研究費 若手研究 
  4. 上間達也 日本放射線技術学会 研究助成 2019・2020年度学術研究班 ”Artificial Intelligence技術を用いたVMAT治療計画の臨床応用に向けた多施設研究”
  5. 村上 悠 “日本放射線腫瘍学会 診療放射線技師海外研修助成事業 派遣員” 2019.
  6. 津野隼人 第75回日本放射線技術学会総会学術大会. JRC2019. Bronze賞. 2019. 横浜.
  7. 松林史泰 日本放射線技術学会 2015年度 研究奨励賞・技術新人賞治療分野
  8. 松林史泰 日本放射線技術学会 2019年度 研究奨励賞・技術奨励賞治療分野
  9. 上間達也 日本放射線技術学会 2020年度 研究奨励賞・技術新人賞治療分野
  10. 松林史泰 特願2020-82274
  11. 松林史泰 特願2020-204818

このページのTOPへ